Business Description
Beam Therapeutics Inc
NAICS : 325411
SIC : 2833
238 Main Street, 9th Floor, Cambridge, MA, USA, 02142
Description
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.14 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.58 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.84 | |||||
| Beneish M-Score | 2235.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -22 | |||||
| 3-Year EPS without NRI Growth Rate | 13.5 | |||||
| 3-Year FCF Growth Rate | -22.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -11.28 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.81 | |||||
| 9-Day RSI | 50.07 | |||||
| 14-Day RSI | 55.6 | |||||
| 6-1 Month Momentum % | -23.96 | |||||
| 12-1 Month Momentum % | -51.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.66 | |||||
| Quick Ratio | 5.66 | |||||
| Cash Ratio | 5.59 | |||||
| Days Sales Outstanding | 1059.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -445.19 | |||||
| Net Margin % | -395.37 | |||||
| ROE % | -34.23 | |||||
| ROA % | -21.01 | |||||
| ROIC % | -77.94 | |||||
| ROC (Joel Greenblatt) % | -135.01 | |||||
| ROCE % | -27.34 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 73.73 | |||||
| PB Ratio | 5.47 | |||||
| Price-to-Tangible-Book | 5.13 | |||||
| Price-to-Free-Cash-Flow | 31.38 | |||||
| Price-to-Operating-Cash-Flow | 23.92 | |||||
| EV-to-EBIT | -13.06 | |||||
| EV-to-Forward-EBIT | -12.02 | |||||
| EV-to-EBITDA | -13.55 | |||||
| EV-to-Forward-EBITDA | -13.06 | |||||
| EV-to-Revenue | 58.17 | |||||
| EV-to-Forward-Revenue | 93.96 | |||||
| EV-to-FCF | 22.96 | |||||
| Price-to-Net-Current-Asset-Value | 6.91 | |||||
| Price-to-Net-Cash | 7.1 | |||||
| Earnings Yield (Greenblatt) % | -7.66 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:BEAM
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 60.27 | ||
| EPS (TTM) ($) | -3.61 | ||
| Beta | 0 | ||
| Volatility % | 89.48 | ||
| 14-Day RSI | 55.6 | ||
| 14-Day ATR ($) | 4.75287 | ||
| 20-Day SMA ($) | 62.3875 | ||
| 12-1 Month Momentum % | -51.37 | ||
| 52-Week Range ($) | 27.77 - 116.91 | ||
| Shares Outstanding (Mil) | 70.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beam Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||